# Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

> **NCT00075270** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 580 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** GW572016 (Lapatinib)

## Key facts

- **NCT ID:** NCT00075270
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2006-10
- **Final completion:** 2012-03
- **Target enrollment:** 580 (ACTUAL)
- **Last updated:** 2015-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00075270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00075270, "Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00075270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*